HumeCare GLP-1

Product Details

HumeCare operates the technology, membership and administrative platform. Medical evaluations, prescribing decisions and continuing clinical management are provided by an independent clinical network rather than HumeCare itself.

What Is HumeCare GLP-1?

HumeCare GLP-1 is an online weight-management program that combines a health assessment, physician review, prescription fulfillment, coaching and progress tracking. It is a healthcare membership rather than one standardized medication, strength or injection volume.

The program currently lists compounded semaglutide and compounded tirzepatide. A clinician determines whether a prescription is appropriate and establishes the dose. Both compounded options are prescription drugs, not vitamins, herbal products or dietary supplements, and neither compounded formulation is FDA approved.

Who May Consider HumeCare GLP-1?

Adults seeking professionally supervised weight-management care may consider completing the online eligibility assessment. One official program page states that applicants with a BMI of 25 or higher may qualify, while HumeCare’s medication safety page describes compounded treatment for an initial BMI of at least 27.

These statements do not guarantee approval. An independent physician reviews the applicant’s medical history, current medicines, weight-related risks and treatment goals. Unexplained weight changes or symptoms suggesting another medical condition may require laboratory testing or an in-person evaluation.

How May HumeCare GLP-1 Support Weight Management?

Semaglutide activates GLP-1 receptors involved in appetite signaling, glucose-dependent insulin release and stomach emptying. These actions may reduce hunger and help some patients feel full for longer when medication is used with nutrition and activity changes.

Tirzepatide activates both GIP and GLP-1 receptors. The prescribing physician selects the medication and adjusts the dose according to clinical appropriateness, tolerability and treatment response.

HumeCare also provides app-based medication tracking, food logging, coaching and body-composition monitoring. These tools may help patients follow their plan, but specific weight loss, muscle retention or symptom outcomes cannot be guaranteed.

Prescription Treatment Information

There is no Supplement Facts panel because HumeCare provides prescription medications rather than dietary supplements.

The medication concentration, injection volume and titration schedule are individualized. HumeCare’s safety information states that a provider may increase the dose approximately every four weeks, but patients must follow their own prescription rather than a general online schedule.

Active Medications

The program offers two prescription incretin medications selected and adjusted by independently licensed physicians.

• Compounded Semaglutide

Compounded semaglutide is a GLP-1 receptor agonist administered by subcutaneous injection. HumeCare does not disclose one universal concentration or dose because the treatment schedule is individually prescribed. The compounded formulation is not FDA approved.

• Compounded Tirzepatide

Compounded tirzepatide activates GIP and GLP-1 receptors and is administered under the skin. The exact concentration, dose and escalation schedule depend on the provider’s prescription and the dispensing pharmacy’s formulation.

Added Ingredients And Allergens

The main HumeCare website refers to supportive ingredients such as glycine and vitamins B6 and B12. However, it does not establish that every compounded semaglutide or tirzepatide prescription contains all three ingredients.

Patients should review their pharmacy label for:

• The complete active formulation
• Medication concentration
• Added vitamins or amino acids
• Preservatives and stabilizers
• Injection-solution ingredients
• Declared allergens
• Storage temperature
• Beyond-use date
• Pharmacy contact information

The precise ingredients may vary by prescription and dispensing pharmacy. Patients with medication or excipient allergies should disclose them before the prescription is prepared.

Potential Benefits

• May provide private access to physician-reviewed weight-management care.
• May support reduced appetite and increased feelings of fullness.
• Provides compounded semaglutide and tirzepatide options when prescribed.
• Provides continuing clinical support and individualized dose management.
• Contains app-based weight, medication and body-composition tracking tools.

Results depend on medical eligibility, medication response, adherence, lifestyle and treatment duration. HumeCare does not guarantee that every applicant will receive medication or achieve a particular result.

Important Limitations

• Compounded semaglutide and tirzepatide are not FDA approved.
• Medication concentration and inactive ingredients may differ between pharmacies.
• Eligibility wording differs between the promotional and medication-safety pages.
• The program automatically renews unless canceled before the renewal date.
• An online consultation may not replace a physical examination or laboratory testing.
• Medication availability can change because of pharmacy capability, regulation or prescribing decisions.
• Exact tirzepatide pricing is not publicly displayed on the reviewed main program page.

HumeCare’s terms state that compounded medications are not equivalent to or interchangeable with FDA-approved brand-name products.

How To Use?

• Complete the health questionnaire accurately and disclose all medicines and medical conditions.
• Use only the medication, concentration and injection volume prescribed for you.
• Inject the medicine under the skin of the abdomen, thigh or upper arm.
• Administer it once weekly on the same day when directed by the provider.
• Rotate injection sites rather than repeatedly using the same location.
• The medication may be used with or without food.
• Do not increase, decrease or stop treatment without speaking to the provider.
• Follow the pharmacy label for refrigeration, storage and disposal requirements.

HumeCare’s safety instructions describe medication supplied in a vial for administration with a needle and syringe. Patients should never estimate syringe units or convert milligrams without pharmacy-specific instructions.

Warnings And Precautions

• Do not use the medication with another GLP-1 or GIP/GLP-1 drug unless specifically directed.
• Do not use it with a personal or family history of medullary thyroid carcinoma.
• Do not use it with Multiple Endocrine Neoplasia syndrome type 2.
• Weight-loss medication should not be used during pregnancy.
• Tell the clinician if you are pregnant, planning pregnancy or breastfeeding.
• Discuss any history of pancreatitis, kidney disease, gallbladder problems or severe digestive disease.
• Tell the provider about diabetic retinopathy, depression or suicidal thoughts.
• Use caution with insulin or sulfonylureas because low blood sugar may occur.
• Disclose prescription drugs, nonprescription medicines, vitamins, herbs and weight-loss supplements.
• Seek urgent help for severe abdominal pain, serious allergic symptoms or signs of dehydration.
• Never reuse or share needles, syringes or medication vials.
• Keep the medicine and injection supplies away from children.

HumeCare advises discontinuing compounded semaglutide or tirzepatide at least two months before a planned pregnancy. Individual instructions should come directly from the prescribing clinician.

Possible Side Effects And Interactions

Tolerance varies between patients. Commonly listed effects include nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, reflux, headache, fatigue, dizziness and injection-site irritation. Serious risks may include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe allergic reactions and low blood sugar.

Semaglutide and tirzepatide delay stomach emptying and may change the absorption of oral medicines. Insulin and sulfonylureas can increase hypoglycemia risk. Patients should consult their clinician or pharmacist before combining treatment with other medication or weight-loss products.

Pros

• Includes review by an independent licensed physician.
• Offers semaglutide and tirzepatide treatment options.
• Includes continuing prescription management and coaching.
• Provides app-based medication and progress tracking.
• Medication is included when prescribed through a partner pharmacy.
• Membership may be canceled before the next renewal.

Cons

• Exact formulation and pharmacy can vary.
• The membership automatically renews.
• Most membership charges are non-refundable.
• The official guarantee descriptions are inconsistent.
• Services are unavailable in four states.

Pricing And Results Guarantee

Current public pricing covers monthly access, medication when prescribed, clinician support, coaching, and program tools.

• Semaglutide: $199
• Tirzepatide: $299

HumeCare’s terms state that certain medicines, formulations, doses or fulfillment options may carry additional charges. The complete price shown at checkout should therefore be reviewed before payment.

Subscription And Refund Conditions

The membership renews automatically at the current rate. Cancellation must be submitted through the account or customer support at least 48 hours before the renewal date.

If the clinical network decides that the customer is ineligible for every available treatment after the first assessment, HumeCare states that the membership fee will be refunded within ten business days. If a device was included, the refund may depend on returning it in its original condition.

Other membership payments are generally non-refundable, and no prorated refund is provided for a partially used membership period.

Pharmacist Note

Confirm the active medication, concentration and injection volume every time a refill arrives. Compounded strengths may vary, so never reuse instructions from a previous vial without checking its label. Tell the clinician about all medicines and contact the pharmacy when storage, dosing or syringe markings are unclear.

FAQ

1. What type of program is HumeCare GLP-1?

HumeCare GLP-1 is a self-pay telehealth weight-management membership providing access to independent physicians, compounded prescription options, pharmacy delivery, coaching, medication tracking and body-composition tools for eligible adults.

2. Which medications does HumeCare offer?

The reviewed program page lists compounded semaglutide and compounded tirzepatide. The prescribing physician determines which option, if any, is clinically appropriate after reviewing the applicant’s health information.

3. How is the medication taken?

The compounded medications are generally injected under the skin once weekly. The exact dose, syringe measurement, concentration and titration schedule must follow the provider’s prescription and pharmacy label.

4. How long does one shipment last?

The publicly displayed program provides an approximate four-week medication supply under a monthly membership. The exact volume and number of doses depend on the prescription and pharmacy formulation.

5. Can it be used with other medications?

Patients must disclose every medicine and supplement. Insulin, sulfonylureas, oral prescriptions and other GLP-1 medicines may create interaction risks or require monitoring and dosage changes.

6. What is the cancellation and refund policy?

Memberships renew automatically. Cancellation must occur at least 48 hours before renewal. Most fees are non-refundable, although ineligible applicants receive a refund and qualifying members may claim the conditional results guarantee.

Medical Disclaimer

HumeCare GLP-1 treatments require evaluation and a prescription from an independently licensed healthcare professional. Eligibility, medication choice, formulation, dosage and monitoring are individualized. These medicines are not suitable for everyone and may cause serious adverse effects.

Compounded semaglutide and compounded tirzepatide are not FDA approved and have not undergone FDA premarket evaluation for safety, effectiveness or manufacturing quality. This page does not replace the prescription label, pharmacy instructions, clinician advice, medication guide or emergency care.

Sources and Product Review Information

• Official Website: HumeCare GLP-1
• Official GLP-1 program page: Compounded medication options, $199 semaglutide pricing, eligibility language and included services.
• Official medication safety information: Administration, contraindications, pregnancy precautions, interactions and adverse effects.
• Official Terms of Service: Platform role, independent clinical network, pharmacy fulfillment, recurring billing, cancellation, refunds and guarantee requirements.
• Official coverage page: Current states and territories where clinical services are available or unavailable.

Affiliate Disclosure: This page may contain affiliate links. If you make a purchase through one of these links, we may earn a commission at no additional cost to you. This does not influence the information presented above, which is based on publicly available product and label information.